当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Anil Patel
One of the most common causes of maternal mortality in the Western world is pregnancy-associated high-risk pulmonary embolism, which results in hemodynamic instability and circulatory failure due to a significant thrombotic pulmonary blockage. The extremely difficult management of these dramatic conditions includes the necessity to immediately decide between pulmonary reperfusion therapy and hemodynamic replacement while taking both maternal and foetal risks into consideration. The relevance of risk stratification in pregnancy-related PE and the data supporting the use of thrombolysis, catheter-directed thrombectomy thrombolysis, surgical embolectomy, and extracorporeal membrane oxygenation are included in this study. The majority of documented cases of high-risk pregnancy-associated PE have been treated with thrombolysis, with good mother and foetal survival rates, and thrombolysis is recommended by despite the absence of comparison studies and strong evidence. Standards for life-threatening PE. Due to the relatively high risk of bleeding, non-fibrinolytic medications may be selected as a first-line treatment for women in the per partum and early post-partum period, if available. A multidisciplinary strategy involving PE response teams and obstetricians is required in all situations involving pregnancy-associated high-risk PE.